PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.
Investor's Business Daily · 6d ago
PTC Therapeutics price target raised to $46 by RBC Capital
RBC Capital analyst Brian Abrahams raised PTC Therapeutics (NASDAQ:PTCT) price target to $46 from $42 and maintained a Sector Perform rating on the shares. This update is followed by phase 3
Seekingalpha · 6d ago
RBC Raises Price Target on PTC Therapeutics to $46 From $42, Sees Translarna Study 041 Data 'Likely Strong Enough' to Maintain EU Marketing, Reimbursement; Sector Perform Kept
MT Newswires · 6d ago
PTC Therapeutics Says Translarna Trial Confirms Treatment Benefits; Shares Rally
MT Newswires · 06/21 12:58
PTC jumps 27% after data for Duchenne muscular dystrophy therapy
PTC Therapeutics (NASDAQ:PTCT), a biotech focused on rare diseases added ~27% in the pre-market Tuesday after disclosing topline data from a placebo-controlled trial for Translarna (ataluren), a drug targeted at patients with
Seekingalpha · 06/21 12:51
PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The call will be accom...
PR Newswire · 06/20 20:00
PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ET
PR Newswire · 06/06 12:00
PTC Therapeutics Reports Positive Preliminary Results From Study of Unesbulin to Treat Leiomyosarcoma
MT Newswires · 06/03 12:42
Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin (PTC596) in advanced leiomyosarcoma (LMS) patients. The results demonstrated that treated patients achieved an 18...
PR Newswire · 06/03 12:00
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 20% Above Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of PTC Therapeutics, Inc. ( NASDAQ:PTCT ) by projecting...
Simply Wall St. · 06/01 13:49
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 36 companies achieved new lows for the year.
Benzinga · 05/31 16:06
BRIEF-FDA Approves Label Extension For Evrysdi For Infants With Spinal Muscular Atrophy Under 2 Months Old · 05/31 05:02
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA).
PR Newswire · 05/31 05:00
PTC Therapeutics Says FDA Approves Neuromuscular Disease Drug for Infants in Label Extension
MT Newswires · 05/31 03:58
UBS Adjusts PTC Therapeutics Price Target to $37 From $40, Maintains Neutral Rating
MT Newswires · 05/27 11:34
Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next
Benzinga · 05/24 19:13
Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder
Benzinga · 05/20 17:50
BRIEF-PTC Therapeutics Receives Positive CHMP Opinion For Upstaza For AADC Deficiency Treatment · 05/20 12:51
PTC Therapeutics gene therapy Upstaza gets EMA panel nod for ultra-rare genetic disorder
A committee of the European Medicines Agency (EMA) recommended the approval of PTC Therapeutics' (NASDAQ:PTCT) one time gene therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults.
Seekingalpha · 05/20 12:50
PTC Therapeutics Reports Positive European Medicines Agency Committee For Medicinal Products For Human Use Opinion For Upstaza For Treatment Of Aromatic L-Amino Acid Decarboxylase Deficiency
– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive
Benzinga · 05/20 12:13
Webull provides a variety of real-time PTCT stock news. You can receive the latest news about Ptc Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).